Drug intelligence / Profile preview

AST-038

Development stage: Preclinical
Lead developer: Astrogen
Modality: Small Molecules

Overview

AST-038 is a preclinical-stage small molecule drug candidate being developed by Astrogen, a South Korean biotechnology company. The drug is intended for the treatment of Neurofibromatosis Type 1 (NF1), a genetic disorder characterized by the growth of tumors along nerves in the skin, brain, and other parts of the body. While Astrogen specializes in therapies for neurological and rare diseases, specific details regarding the biological target and mechanism of action for AST-038 have not yet been publicly disclosed.

Beyond the preview

Go deeper on AST-038.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-038.

Explore the full profile